Goldman Sachs initiated Intellia Therapeutics (NTLA +4.5%) with a Buy rating, PT $33; stock has surged 94% in the past 6 months, Wall Street Analysts (PT, $30) and Quant Rating is Bullish.
Analyst Salveen Richter sees “key value-driving events” over the next 12 months, including proof-of-concept data for lead program NTLA-2001, the first systemically-delivered CRISPR/Cas9 therapy to enter the clinic by the end of 2020 for transthyretin amyloidosis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.